NCX 1101

Drug Profile

NCX 1101

Latest Information Update: 24 Jun 2001

Price : $50

At a glance

  • Originator NicOx
  • Class
  • Mechanism of Action Cyclooxygenase inhibitors; Nitric oxide donors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Colorectal cancer

Most Recent Events

  • 24 Jun 2001 Discontinued-Preclinical for Colorectal cancer in France (Unknown route)
  • 05 Nov 1998 Preclinical development for Colorectal cancer in France (Unknown route)
  • 05 Nov 1998 New profile
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top